One-Health Anti Microbial Resistance (OH AMR)
Partnership website: https://www.jpiamr.eu/activities/one-health-amr/
The OH AMR partnership aims to coordinate and align activities and funding between countries as well as with the Commission. It will also facilitate national coherence between different services and ministries with responsibility for the various aspects of antimicrobial resistance (AMR) (e.g. human health, agriculture, environment, industry, finances).
The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, by reducing the threat of AMR.
Expected impact
- Novel solutions to prevent and treat infectious diseases affected by AMR, improved diagnosis and control of the spread of resistant microorganisms, testing and validation of such solutions and facilitating their uptake or implementation.
- Decreased burden of infectious diseases, notably due to AMR pathogens and progress towards Sustainable Development Goal No. 3 ‘Ensure healthy lives and promote well-being for all at all ages’.
- Closed knowledge gaps on AMR, support provided to regulatory science and inform policymaking.
Timeline & key documents
- More information in the Draft outline of partnership proposal (February 2022)
- The CSA Design OH AMR was launched in May 2022 and is leading the development of the One Health AMR Partnership, in collaboration with the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR).
- A first draft of the European Partnership OH AMR Strategic Research and Innovation Agenda was published in May 2023. The final text of the SRIA is foreseen to be submitted in 2024
- Launch of the first call and start of activities is foreseen for 2025
Contact
- More information in the Draft outline of partnership proposal (February 2022)
- The CSA Design OH AMR was launched in May 2022 and is leading the development of the One Health AMR Partnership, in collaboration with the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR).
- A first draft of the European Partnership OH AMR Strategic Research and Innovation Agenda was published in May 2023. The final text of the SRIA is foreseen to be submitted in 2024
- Launch of the first call and start of activities is foreseen for 2025
Contact
Commission services: RTD-COMBATTING-DISEASES@ec.europa.eu
Contact JPIAMR: ohamr@vr.se
What are partnerships?
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
How to use partnerships?
-
orientation
Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points. -
networking
Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents. -
ecosystem analysis
Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain. -
steering the agenda
Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.
Testimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
